Xcout IntelKALA BIO, Inc. competitors & alternatives
The 12 closest competitors and alternatives to KALA BIO, Inc. among biotech companies — ranked by similarity to what KALA BIO, Inc. actually does, not by market-cap band.
Subscribe to see KALA BIO, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About KALA BIO, Inc.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
KALA BIO, Inc. at a glance
KALA BIO, Inc. is a biotech company headquartered in Arlington, United States. It is publicly listed (KALA) with a market capitalisation of $7M. Xcout tracks 35 named people at KALA BIO, Inc., including Avi Minkowitz (CEO, CFO & Director).
KALA BIO, Inc. leadership
- Avi MinkowitzCEO, CFO & Director
- Mary ReumuthChief Financial Officer
- Francis S. MahChief Medical Advisor
- Justin HanesFounder & Chair of the Scientific Advisory Board
- Josiah CraverSenior Vice President & Corporate Controller
- Vincent KosewskiSenior Vice President of Manufacturing & Supply Chain Management
29 more named people on record for KALA BIO, Inc., with roles, board committees and tenure — see the full roster →
Top 12 KALA BIO, Inc. competitors
Ranked by semantic similarity — how close each company is to KALA BIO, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Similar biotech company
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Biotechnology
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
Similar biotech company
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Biotechnology
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Similar biotech company
Kernal Biologics is an onco-selective mRNA therapeutics company located in Cambridge, Massachusetts, that creates mRNA therapies designed to instruct specific cells on how to make proteins.
Biotechnology
Korsana Biosciences is a private biotechnology research company founded in 2024 and headquartered in Waltham, Massachusetts.
Biotechnology
Memento Medicines, Inc. is a privately held biotechnology company headquartered in Boston, Massachusetts, focused on developing novel biologic therapies for retinal diseases.
Biotechnology
MCAL Therapeutics Inc. is a biotechnology company developing synthetic, rabbit-inspired lipid eye drops and extended-release drug delivery platforms. Its lead candidate, MCAL-201, is designed to treat evaporative dry eye disease by restoring the tear film's protective lipid barrier.
Biotechnology
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Biotechnology
Akagera Medicines is a private Delaware-registered company headquartered in Boston, Massachusetts. The company develops novel and patented liposomal formulations of antibacterial drugs.
Similar biotech company
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of KALA BIO, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for KALA BIO, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →